Skip to main content
    H

    Halozyme Therapeutics Inc (HALO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $96.50
    -3.77 (-3.76%)

    Market Cap: $11.43B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Halozyme Therapeutics Inc (HALO) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Halozyme Therapeutics (HALO) is expected to report earnings on Jan 26, 2027. In the quarter ended Sep 30, 2026, Halozyme Therapeutics reported EPS of $2.27, above the $2.17 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    70%(28/40)
    Avg Surprise
    +6.79%
    Streak
    2 Q

    Upcoming Estimates

    Reports Jan 26, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.70
    Range$2.53 - $2.92
    11 analysts
    Revenue Consensus
    $560.07M
    Range$529.20M - $603.03M
    9 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$2.33
    Range$2.32 - $2.34
    3 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$2.34-0.4%
    60d ago$2.34-0.4%
    30d ago$2.34-0.4%
    7d ago$2.330.0%
    Current$2.33
    Revenue Consensus
    $488.72M
    Range$478.00M - $499.43M
    2 analysts

    Next Report

    HALO has an expected report date of Jan 26, 2027.

    HALO Earnings Call

    The latest HALO earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, HALO beat 28, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $492.97M, up 39.2% from $354.26M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$2.27$2.17N/A+4.61%Beat+32.0%61 up, 0 downNov 5, 2026$492.97M
    Jun 30, 2026$2.17$1.73$1.72 - $1.90+25.43%Beat+40.9%61 up, 0 downAug 6, 2026$481.00M
    Mar 31, 2026$1.22$1.76N/A-30.61%Miss+10.0%52 up, 1 downMay 11, 2026$376.71M
    Dec 31, 2025-$0.24$2.20$2.14 - $2.23-110.91%Miss-119.0%55 up, 0 downFeb 17, 2026$451.77M
    Sep 30, 2025$1.72$1.63$1.47 - $1.69+5.52%Beat+35.4%7N/ANov 3, 2025$354.26M
    Jun 30, 2025$1.54$1.27$1.00 - $1.41+21.26%Beat+69.2%71 up, 0 downAug 5, 2025$325.72M
    Mar 31, 2025$1.11$0.95$0.88 - $0.99+16.84%Beat+40.5%60 up, 1 downMay 6, 2025$264.86M
    Dec 31, 2024$1.26$1.16$1.11 - $1.23+8.73%Beat+53.7%60 up, 2 downFeb 18, 2025$298.01M
    Sep 30, 2024$1.27$0.98$0.93 - $1.05+29.59%Beat+69.3%80 up, 0 downOct 31, 2024$290.08M
    Jun 30, 2024$0.91$0.76$0.73 - $0.87+19.74%Beat+23.0%71 up, 0 downAug 6, 2024$231.35M
    Mar 31, 2024$0.79$0.70$0.63 - $0.83+12.86%Beat+68.1%60 up, 0 downMay 7, 2024$195.88M
    Dec 31, 2023$0.82$0.83$0.79 - $0.85-1.20%Miss+70.8%62 up, 0 downFeb 20, 2024$230.04M
    Sep 30, 2023$0.75$0.71$0.66 - $0.78+5.63%Beat+1.4%60 up, 2 downNov 6, 2023$216.03M
    Jun 30, 2023$0.74$0.64$0.57 - $0.66+15.63%Beat+39.6%61 up, 0 downAug 8, 2023$221.04M
    Mar 31, 2023$0.47$0.48$0.39 - $0.56-2.08%Miss0.0%60 up, 1 downMay 9, 2023$162.14M
    Dec 31, 2022$0.48$0.47$0.42 - $0.53+2.13%Beat+14.3%60 up, 0 downFeb 21, 2023$181.50M
    Sep 30, 2022$0.74$0.51$0.42 - $0.58+45.10%Beat+34.5%52 up, 0 downNov 8, 2022$208.98M
    Jun 30, 2022$0.53$0.50$0.43 - $0.57+6.00%Beat-19.7%60 up, 0 downAug 9, 2022$152.37M
    Mar 31, 2022$0.47$0.49$0.44 - $0.53-4.08%Miss+27.0%62 up, 0 downMay 10, 2022$117.28M
    Dec 31, 2021$0.42$0.41$0.37 - $0.43+2.44%Beat-16.0%83 up, 0 downFeb 22, 2022$102.00M
    Sep 30, 2021$0.55$0.48N/A+14.58%Beat+120.0%N/AN/ANov 2, 2021$115.83M
    Jun 30, 2021$0.66$0.44$0.32 - $0.60+50.00%Beat+247.4%9N/AAug 9, 2021$136.46M
    Mar 31, 2021$0.37$0.31$0.26 - $0.37+19.35%BeatN/A9N/AMay 10, 2021$89.02M
    Dec 31, 2020$0.50$0.53$0.45 - $0.59-5.66%MissN/A10N/AFeb 23, 2021$121.70M
    Sep 30, 2020$0.25$0.21$0.12 - $0.23+19.05%BeatN/A10N/ANov 2, 2020$65.32M
    Jun 30, 2020$0.19$0.25$0.09 - $0.42-24.00%MissN/A11N/AAug 10, 2020$55.22M
    Mar 31, 2020-$0.04-$0.04-$0.14 - $0.160.00%In line-500.0%11N/AMay 11, 2020$25.35M
    Dec 31, 2019-$0.24-$0.14-$0.25 - $0.11-71.43%MissN/A10N/AFeb 24, 2020$53.66M
    Sep 30, 2019-$0.17-$0.13-$0.18 - -$0.05-30.77%MissN/A10N/ANov 12, 2019$46.23M
    Jun 30, 2019-$0.10-$0.15-$0.22 - -$0.03+33.33%BeatN/A10N/AAug 6, 2019$39.15M
    Mar 31, 2019$0.01$0.05-$0.11 - $0.11-80.00%MissN/A10N/AMay 7, 2019$56.95M
    Dec 31, 2018-$0.01-$0.03-$0.07 - $0.04+66.67%Beat-101.2%11N/AFeb 21, 2019$60.23M
    Sep 30, 2018-$0.19-$0.23-$0.25 - -$0.20+17.39%Beat-1050.0%10N/ANov 6, 2018$25.56M
    Jun 30, 2018-$0.16-$0.22-$0.25 - -$0.18+27.27%BeatN/A9N/AAug 7, 2018$35.20M
    Mar 31, 2018-$0.19-$0.22-$0.28 - -$0.13+13.64%BeatN/A11N/AMay 10, 2018$30.87M
    Dec 31, 2017$0.85$0.77$0.53 - $0.88+10.39%BeatN/A11N/AFeb 20, 2018$189.56M
    Sep 30, 2017$0.02-$0.11-$0.29 - $0.25+118.18%BeatN/A9N/ANov 7, 2017$63.73M
    Jun 30, 2017-$0.23-$0.24-$0.26 - -$0.22+4.17%BeatN/A10N/AAug 8, 2017$33.75M
    Mar 31, 2017-$0.26-$0.24N/A-8.33%MissN/AN/AN/AMay 9, 2017$29.57M
    Dec 31, 2016-$0.21-$0.28N/A+25.00%Beat-800.0%N/AN/AFeb 28, 2017$39.00M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $4.13, down 2.4% from the year before. It was -$0.81 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$4.13-2.4%
    Dec 31, 2024$4.23+52.2%
    Dec 31, 2023$2.78+25.2%
    Dec 31, 2022$2.22+11.0%
    Dec 31, 2021$2.00+122.2%
    Dec 31, 2020$0.90N/A
    Dec 31, 2019-$0.50N/A
    Dec 31, 2018-$0.55-244.7%
    Dec 31, 2017$0.38N/A
    Dec 31, 2016-$0.81N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,400 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,37012
    2026Q2Jun 30, 20265,71210
    2026Q1Mar 31, 20266,89913
    2025Q4Dec 31, 20255,75711
    2025Q3Sep 30, 20255,8779
    2025Q2Jun 30, 20257,79312
    2025Q1Mar 31, 20256,56811
    2024Q4Dec 31, 20247,21011

    2026Q3 Earnings Call

    Opening remarks

    Tram Bui Vice President of Investor Relations Thank you, operator. Good afternoon, and welcome to Halozyme's Third Quarter 2026 Financial and Operating Results Conference Call. In addition to the press release issued today after the market close, you can find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website. Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business; and Darren Snellgrove, our Chief Financial Officer, who will review our financial results and outlook. On today's call, we will be making forward-looking statements as outlined on Slide 2. I would also refer you to our SEC filings for a full list of risks and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed. Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation. I will now turn the call over to Dr. Helen Torley, and we will start on Slide 3.

    Helen Torley President and Chief Executive Officer Thank you, Tram, and good afternoon, everyone. I'm pleased to report another exceptionally strong quarter for Halozyme as more patients, physicians and health care systems experience the benefits of subcutaneous delivery with ENHANZE. This is reflected in the record total and royalty revenues. And operationally, we continue to demonstrate new growth opportunities resulting from our compounding platform engine, ENHANZE. In and post the quarter, we significantly expanded the ENHANZE opportunity with 3 current partners expanding their agreements to add 4 new target nominations. Additionally, 3 ENHANZE-enabled programs, 1 each from Pfizer, Incyte and argenx, advanced into Phase I development. And GSK plans to initiate a Phase Ib study of a subcutaneous formulation of belantamab with ENHANZE. With this planned start, we are on track to achieve 13 ENHANZE programs in clinical development by year-end. Importantly, we also advanced our 2 hyperconcentration technologies, Hypercon and Aerocon, the new name for Surf Bio, moving these closer to clinical testing. All of this contributed to the record total revenue, royalty revenue and adjusted EBITDA for Q3. Total revenue increased 39% year-over-year to $493 million, driven by royalty revenue, which increased 44% to a record $341 million. These results reflect the continued growth of our established commercial partner product portfolio and the growing contributions from the newer launches, which is resulting in a diversified and growing set of royalty revenue streams. Profitability remained strong during the quarter with adjusted EBITDA of $336 million and an adjusted EBITDA margin of 68%, reflecting our disciplined execution. Based on this strength, we are raising our full year 2026 financial guidance. Darren will be discussing this in greater detail. Turning to Slide 4.

    Frequently Asked Questions About HALO

    When is Halozyme Therapeutics's next earnings date?

    Halozyme Therapeutics's next earnings report is expected for Jan 26, 2027.

    Did HALO beat earnings estimates last quarter?

    Yes. Halozyme Therapeutics reported EPS of $2.27 for the quarter ended Sep 30, 2026, above the $2.17 estimate, a 4.61% surprise.

    What EPS do analysts expect from HALO next quarter?

    The consensus EPS estimate for Halozyme Therapeutics for the quarter ending Dec 31, 2026 is $2.70 from 11 analysts, with estimates from $2.53 to $2.92.

    How often does HALO beat earnings estimates?

    Halozyme Therapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of -7.39%.